

**(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. AU 2015293652 B2

(54) Title
Sample analysing device

(51) International Patent Classification(s)
G01N 33/558 (2006.01)

(21) Application No: **2015293652** (22) Date of Filing: **2015.07.24**

(87) WIPO No: **WO16/012812**

(30) Priority Data

(31) Number **1413157.7** (32) Date **2014.07.24** (33) Country **GB**

(43) Publication Date: **2016.01.28**
(44) Accepted Journal Date: **2020.07.02**

(71) Applicant(s)
Intelligent Fingerprinting Limited

(72) Inventor(s)
Hudson, Mark;Johnson, Jonathan;Russell, David;Goetz, Stephan;Stuchinskaya, Tanya

(74) Agent / Attorney
Griffith Hack, GPO Box 4164, Sydney, NSW, 2001, AU

(56) Related Art
DE 19622503 A1
US 20100143891 A1
US 2008/0194041 A1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2016/012812 A1

(43) International Publication Date
28 January 2016 (28.01.2016)

(51) International Patent Classification:
G01N 33/558 (2006.01)

(74) Agent: BOULT WADE TENNANT; Verulam Gardens,
70 Grays Inn Road, London, Greater London WC1X 8BT
(GB).

(21) International Application Number:

PCT/GB2015/052157

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date:

24 July 2015 (24.07.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1413157.7 24 July 2014 (24.07.2014) GB

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))



WO 2016/012812 A1

(54) Title: SAMPLE ANALYSING DEVICE

(57) Abstract: The present invention relates to a device and a method for analysing a sample comprising from 0.1 pg to 1 µg of analyte, and more specifically to a lateral flow device and a method for testing the presence of very low amounts of drugs or drug metabolites in a sample. The present invention also relates to a method of dissolving a bodily fluid.

SAMPLE ANALYSING DEVICE

TECHNICAL FIELD

The present invention relates to a device and a method for analysing a sample comprising from 0.1 pg to 1 µg of analyte, and more specifically to a lateral flow device and a method for testing the presence of very low amounts of drugs or drug metabolites in a sample. The present invention also relates to a method of dissolving a bodily fluid.

BACKGROUND

Doctors, health-care workers, rehab clinics, coroners, employers, government agencies, sports groups, the police and the public in general are interested in the presence and levels of various substances in bodily fluids including blood, urine, saliva and sweat. Among the substances which have been measured in clinical analysis for a long time are glucose, cholesterol, various enzymes such as amylase and creatine kinase, and drugs and their metabolites.

Lateral flow testing devices are widely used for the detection of specific compounds, or analytes, in a biological fluid specimen. One or more reagents are positioned on a solid material, such as a cellulose or paper strip, the reagents being selected as necessary or helpful in detection of the analyte in question. A fluid sample is deposited onto the strip and will migrate, by capillary action, along the strip where the chemical reactions may take place, depending on the presence or absence of the analyte, in situ.

Devices for testing for the presence of substances of abuse, for example, drugs regulated by law with respect to possession and use, by chemical analysis of a biological fluid sample are well known. In the past, for example, methamphetamines have been detected using a number of techniques, including thin layer chromatography (TLC), gas chromatography (GC), and high performance liquid chromatography (HPLC). These methods generally involve chemical extractions of the drugs, complicated procedures requiring highly trained personnel and lengthy assay times. Thin layer chromatography is labour intensive and lacks sensitivity. Gas chromatography and high performance liquid chromatography, each of which is also labour intensive, require highly trained personnel to carry out extractions of the analyte from the biological matrix. In addition, gas chromatography normally requires a derivation step.

More recently, competitive binding immunoassays have been developed for testing a biological fluid for the presence of certain substances of abuse, and these provide a preferable alternative to the physical methods described briefly hereinabove.

Immunoassay test devices generally include an absorbent, fibrous strip having one or more reagents incorporated at specific zones on the strip. The fluid sample is deposited onto the strip and by capillary action the sample will migrate along the strip, entering specific reagent zones in which a chemical reaction may take place. At least one reagent is included which manifests a detectable response, for example a colour change, in the presence of a certain amount of the substance of interest.

One limitation with known lateral flow "drugs of abuse" testing devices and methods based on immunoassay technologies is that the devices are not sensitive enough to qualitatively and/or quantitatively detect low amounts of the analyte(s) in question in a reliable manner. Such a limitation means that biological samples must generally be provided to known devices in large amounts and/or with a high concentration of analyte, for example in the form of blood or urine.

In some forms, the present disclosure may overcome at least some of the disadvantages of the prior art or to provide a commercially useful alternative thereto.

In some forms, the present disclosure may provide an easy-to-use, inexpensive device and method having increased sensitivity to an analyte(s) in a sample without the need for more complicated, costly confirmation procedures.

In some forms, the present disclosure may provide a more reliable device and method for qualitatively and/or quantitatively analysing a sample comprising a low amount of analyte(s).

In some forms, the present disclosure may provide a method of dissolving a bodily fluid for use in the device and method of analysing a sample.

It is to be understood that, if any prior art is referred to herein, such reference does not constitute an admission that the prior art forms a part of the common general knowledge in the art, in Australia or any other country

SUMMARY

Each aspect or embodiment as defined herein may be combined with any other aspect(s) or embodiment(s) unless clearly indicated to the contrary. In particular any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.

In a first aspect the present disclosure provides a method for analysing a sample

comprising from 0.1 pg to 1 µg of an analyte, the method comprising:

providing a sample, the sample containing or not containing from 0.1 pg to 1 µg of the analyte of interest;

dissolving at least a portion of the sample in a buffer to form a dissolved sample solution;

contacting at least a portion of the dissolved sample solution with a probe zone comprising a labelled probe to dissolve at least a portion of the labelled probe and allow the labelled probe to bind with the analyte, where present, in the portion of the dissolved sample solution to form a labelled probe-analyte complex;

passing the labelled probe and/or labelled probe complex through a test site comprising a first immobilised capture reagent capable of binding to the labelled probe;

determining whether or not the amount of analyte, if any, in the sample exceeds a threshold value by detecting the amount of labelled probe in the test site;

wherein the sample comprises finger-sweat and/or palm-sweat and/or toe-sweat;

wherein the sample is provided on a sample receiving portion of a lateral flow device, the device further comprising:

the probe zone downstream of the sample receiving portion;

the test site downstream of the probe zone, comprising a first immobilised capture reagent capable of binding to the labelled probe;

the device being configured to permit movement of a buffer from the sample receiving portion to the probe zone and from the probe zone to the test site;

wherein the sample provided is substantially dry, such that the sample comprises insufficient liquid to move from the sample receiving portion to the probe zone wherein the sample is provided directly to the sample receiving portion;

wherein dissolving at least a portion of the sample in a buffer to form a dissolved sample solution is carried out by providing the buffer upstream of the sample receiving portion and passing the buffer through the sample receiving portion.

5 Other preferred embodiments of the device and methods according to the disclosure appear throughout the specification and in particular in the examples.

The present inventors have surprisingly found that the lateral flow device and the method of the present disclosure are able to reliably detect whether or not low amounts, for 10 example from 0.1 pg to 1 µg, of analyte are present in a sample. If the analyte is present, the device and method can also provide precise information regarding the identity and amount of analyte present in the sample.

Without wishing to be bound by theory, it is thought that the device and method 15 described herein are able to detect and quantify low amounts of analyte in samples having low volumes. For example, the sample may be a substantially dry sample, such that the sample, when deposited, comprises insufficient liquid to move by capillary action through a substrate without being dissolved in a set volume of buffer.

20 The present inventors have now surprisingly found that, when a very low volume/mass of a substantially dry sample is deposited over a large surface area, low amounts of analyte in the sample are able to be detected by using a buffer to rapidly release the analyte (e.g. a drug or drug metabolite) from the sample (e.g. a fingerprint). As the buffer passes through the sample, the analyte molecules concentrate at the buffer solvent front, where 25 they are then brought into contact with labelled probes (e.g. labelled antibodies) specific to the analyte.

DETAILED DESCRIPTION

30 Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. The meaning and scope of the terms should be clear, however, in the event of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition.

Lateral flow immunoassays are simple tests for rapid detection of the presence or absence of a target analyte in a sample for home testing, point of care testing, or laboratory applications. Lateral flow devices advantageously may utilise a solid support through which a mobile phase (e.g., a buffer) can flow through by capillary action to a

5 reaction matrix where a detectable signal, such as colour changes or colour differences at a test site, may be generated to indicate the presence or absence of the target analyte. As used herein, the term "*capillary action*" refers to the process by which a molecule is drawn across the lateral test device due to such properties as surface tension and attraction between molecules.

10 The lateral flow device as described herein is for use in an immunoassay i.e. a method for analysing a sample comprising from 0.1 pg to 1 µg of analyte. The immunoassay comprises a competitive binding assay, where any labelled probe (e.g. antibody) not bound to analyte provides an identifiable signal in the test site whilst any labelled probe 15 bound to analyte, e.g. in the form of an immunocomplex, passes through the test site and does not provide an identifiable signal in the test site. As the number of analyte molecules present in the sample increases, the amount of unbound labelled probe passing through the test site decreases. Thus the higher the level of analyte in the sample, the weaker the identifiable signal at the test site will be. Such a device/method 20 allows qualitative tests to be undertaken, i.e. whether or not the sample contains an analyte of interest. Such a device/method also allows quantitative tests to be undertaken by measuring the intensity of the signal at the test site. The higher the intensity of the signal, the lower the amount of analyte in the sample.

25 In a first embodiment, the present disclosure provides a lateral flow device for analysing a sample comprising from 0.1 pg to 1 µg of analyte, the device comprising:
a sample receiving portion;
a probe zone downstream of the sample receiving portion, the probe zone comprising a labelled probe capable of binding to the analyte; and
30 a test site, downstream of the probe zone, the test site comprising a first immobilised capture reagent capable of binding to the labelled probe;
the device being configured to permit movement of a buffer from the sample receiving portion to the probe zone and from the probe zone to the test site.

In use, the labelled probe will bind to the immobilised first capture reagent in the test site, unless it is blocked by analyte present in the sample.

As used herein, the term “*sample*” refers to a fluid sample which may or may not contain 5 one or more analytes of interest. A sample may comprise a liquid body fluid (for example, urine, blood, plasma, serum, sweat, saliva, ocular fluid, spinal fluid, and the like) from humans or animals.

Advantageously, the device is for analysing a sweat sample, in some forms an eccrine sweat sample. Advantageously, the device is for analysing a finger-sweat and/or palm-sweat and/or toe-sweat sample. Advantageously, the device is for analysing a finger-sweat sample. The term “*finger-sweat*” refers to sweat secreted by sweat glands in the skin of fingers of mammals, including humans. Finger-sweat includes sweat deposited as an impression of a finger’s ridge pattern, i.e. a latent fingerprint. The term “*palm-sweat*” refers to sweat secreted by sweat glands in the skin of palms of mammals, 15 including humans. The term “*toe-sweat*” refers to sweat secreted by sweat glands in the skin of toes of mammals, including humans. Toe-sweat includes sweat deposited as an impression of a toe’s ridge pattern, i.e. a latent toe-print.

Advantageously the device is for analysing a sample comprising from 0.1 pg to 1 µg, or 20 from 0.1 pg to 500 ng, or from 0.1 pg to 200 ng, or from 0.1 pg to 100 ng, or from 0.1 pg to 50 ng, or from 0.1 pg to 10 ng, or from 0.1 pg to 5 ng of analyte. Advantageously, the device is for analysing a sample comprising from 0.5 pg to 4 ng, or from 0.5 pg to 3 ng, or from 1 pg to 2 ng, or from 1 pg to 1 ng, or from 1 pg to 500 pg, or from 1 pg to 400 pg, 25 or from 1 pg to 300 pg, or from 2 pg to 250 pg, or from 3 pg to 225 pg, or from 5 pg to 200 pg of analyte.

Advantageously the analyte comprises a drug metabolite and/or a drug.

The sample receiving portion is for receiving the sample, and may be comprised, for 30 example, of a fibrous material which advantageously absorbs the sample.

Advantageously, the sample receiving portion is located on a permeable membrane which comprises one or more of cotton, glass fibre, rayon, polyester, nylon, cellulose, nitrocellulose and spun polyethylene. More advantageously, the sample receiving 35 portion is located on a permeable membrane comprising Fusion 5, available from GE

Healthcare. Fusion 5 is advantageous because it allows the sample on the sample receiving portion to be visualised, for example with a camera, and/or recorded, thereby increasing the accuracy and reliability of any tests undertaken using the device. In particular, visualisation may be useful because the analyser can confirm whether or not

5 the sample receiving portion has received a sample, for example a fingerprint.

Advantageously the sample receiving portion comprises one or more indentations and/or lines configured to concentrate and/or guide the sample downstream to the probe zone. Indentations and/or lines on the sample receiving portion may increase the speed of flow

10 of the buffer downstream towards the probe zone and partition the sample receiving portion into separate channels. In one embodiment, the lines comprise hydrophobic ink.

Advantageously, the sample receiving portion is configured to receive the fingerprint of an average adult human. Advantageously the sample receiving portion has an area of

15 100 mm² to 400 mm² or from 200 mm² to 350 mm², or from 250 mm² to 350 mm².

Advantageously, the sample receiving portion has an area of 275 mm² to 325 mm².

Alternatively, advantageously, the sample receiving portion is configured to receive the fingerprint of a neonate, the sample receiving portion advantageously having an area of 25 mm² to 75 mm², or from 30 mm² to 60 mm². Advantageously, the sample receiving

20 portion is substantially oblong, substantially circular or substantially oval.

Advantageously, The sample receiving portion is configured such that the area of the sample received by one person, for example in the form of a fingerprint, is substantially the same as the area of the sample received by another person of similar age. Such a configuration of sample receiving portion provides better normalised results from sample

25 to sample.

Advantageously, The device may further comprise a buffer receiving portion upstream of the sample receiving portion, the device being configured to permit movement of a buffer from the buffer receiving portion to the sample receiving portion.

30

Advantageously, The device may further comprise a reservoir for holding a buffer, the device being configured such that, in use, the movement of a buffer from the reservoir to the buffer receiving portion is permitted.

Advantageously, The reservoir has a volume of from 100 to 500 μ l. Advantageously, the reservoir has a volume of from 100 to 450 μ l, or from 100 to 400 μ l, or from 100 to 350 μ l, or from 100 to 300 μ l, or from 100 to 250 μ l, or from 100 to 200 μ l. Alternatively, advantageously, the reservoir has a volume of from 125 to 300 μ l, or from 150 to 250 μ l, 5 or from 175 to 215 μ l. Alternatively, advantageously, the reservoir has a volume of from 150 to 550 μ l, or from 200 to 500 μ l, more advantageously from 250 to 400 μ l, or from 300 to 375 μ l, most advantageously from 325 to 350 μ l.

Advantageously, The reservoir may contain from 100 to 500 μ l of buffer. More 10 advantageously, the reservoir contains from 100 to 450 μ l, or from 100 to 400 μ l, or from 100 to 350 μ l, or from 100 to 300 μ l, or from 100 to 250 μ l, or from 100 to 200 μ l of buffer. Alternatively, advantageously, the reservoir contains from 125 to 300 μ l, or from 150 to 250 μ l, or from 175 to 215 μ l of buffer. Alternatively, advantageously, the 15 reservoir contains from 150 to 550 μ l, or from 200 to 500 μ l of buffer. More advantageously, the reservoir contains from 250 to 400 μ l of buffer, or from 300 to 375 μ l, most advantageously from 325 to 350 μ l of buffer.

The reservoir may be a buffer blister. The term "*buffer blister*" refers to a sealed reservoir containing a volume of buffer, at least a portion of which is released on opening 20 the blister, for example by piercing (a wall of) the blister. Buffer blisters are advantageous because the buffer therein may, for example, be kept sterile until the moment of release. Buffer blisters are also advantageous because it is easy to observe that the blister is opened / broken, thus reducing the risk of the buffer therein being tampered with before use.

25 The buffer may comprise a water miscible organic solvent, a surfactant, advantageously a detergent, and a buffering agent. It is advantageous that the buffer comprises all of the three components mentioned above. In particular, the buffer as described herein advantageously flows in a polarised manner downstream through the device at a controlled flow rate by capillary action, meaning that the flow rate is consistent and predictable from the moment of being received at the sample receiving portion. The 30 buffer is also advantageously effective at solubilising the analyte at the solvent front, thereby presenting the analyte to the antibody in a concentrated, efficient and reproducible way. The buffer's individual components and preferred amounts thereof are described in further detail below.

Water miscible solvents are known in the art. The water miscible organic solvent may comprise one or more of ethanol, methanol and tetrahydrofuran. Advantageously, the buffer comprises 10 to 30 v/v % water miscible organic solvent. More advantageously, 5 the buffer comprises from 15 to 25 v/v %, or from 18 to 22 v/v % water miscible organic solvent. The water miscible organic solvent helps hydrophilic and hydrophobic molecules partition in water.

Surfactants are known in the art and may include any molecule that forms micelles, for 10 example amphiphilic molecules. The surfactant may comprise one or more of Tween-20, Tween 80, Triton X-100, tetraoctyl ammonium bromide, Polyethylene glycol (PEG) and octanoic acid. Alternatively, advantageously, the surfactant comprises one or more of Tween-20, Tween 80, Triton X-100, Triton X-114, tetraoctyl ammonium bromide, 15 Polyethylene glycol (PEG) and octanoic acid. More advantageously, the surfactant comprises one or more of Tween-20, Tween 80, Triton X-100 and tetraoctyl ammonium bromide. Alternatively, advantageously, the surfactant comprises one or more of Tween-20, Tween 80, Triton X-100, Triton X-114 and tetraoctyl ammonium bromide. More 20 advantageously, the surfactant comprises Triton X-114. Advantageously, the buffer comprises 0.1 to 0.30 w/v % surfactant. More advantageously, the buffer comprises 0.10 to 0.25 w/v %, or 0.10 to 0.20 w/v %, or 0.12 to 0.17 w/v % surfactant. The surfactant, advantageously a detergent, is thought to aid release of analyte, e.g. drugs and/or drug metabolites, from the sample and thereby increase the accuracy of the test. The surfactant molecules are advantageously present in a concentration above their 25 critical micelle concentration (CMC). The micelles thus present within the surfactant are therefore able to act as a carrier for the hydrophobic analyte, e.g. drugs and drug metabolites, and allow presentation of said analyte to the probe, e.g. an antibody.

Suitable buffering agents are known in the art. The buffering agent may comprise one or 30 more of HEPES, Tris, TRIZMA and phosphate buffer. Advantageously, the buffer comprises 5 to 100 mM buffering agent. More advantageously, the buffer comprises 5 to 75 mM, or 5 to 50 mM, or 5 to 25 mM, or 5 to 15 mM, or 5 to 10 mM, or 6 to 9 mM, or 7 to 8 mM buffering agent. The buffering agent is thought to assist in increasing the solubility of the analyte, e.g. drugs and/or drug metabolites, based on their pKa and PI values.

The buffer may further comprise a salt. The salt may be selected from NaCl, KCl or a mixture thereof. It is thought that when the buffer further comprises a salt, the stringency of the test is improved, for example, an increased level of salt in the buffer may help to reduce the intensity of background noise when analysing the test site(s) and/or the

5 control site and/or the normalisation site.

The buffer may further comprise one or more anti-oxidants. Suitable anti-oxidants include ethyl acetate, methyl anthranilate, 2-pentyl butyrate and ethyl butyrate. Anti-oxidants may help to prevent the oxidation of the analyte or metabolite thereof and any

10 organic material in the sample, such as fingerprint lipids. This is desirable because, if the analyte and/or metabolite thereof is oxidised, its properties (e.g. its charge) may change. Any changes in physical or chemical properties could interfere with the analyte's or metabolite's ability to bind with the probe (e.g. an antibody) and therefore such changes are advantageously avoided by the presence of one or more anti-oxidants

15 in the buffer.

The buffer may further comprise an emulsifier. Advantageously, the emulsifier is selected from deoxycholate, cholesterol and combinations thereof. More advantageously, the emulsifier is deoxycholate. Without wishing to be bound by theory, an emulsifier such as deoxycholate helps to present any analyte or metabolites thereof in the sample to the probe. This is thought to be achieved by the emulsifier aiding presentation of any hydrophobic analyte or metabolite to the labelled probe.

20 Downstream of the sample receiving portion is the probe zone. Advantageously, in use, the buffer (comprising the dissolvable elements, e.g. analyte, from the sample) is drawn into and through the labelled probe zone, which releases a labelled probe into the buffer. The labelled probe is advantageously located on a permeable membrane, wherein the permeable membrane may comprise one or more of nitrocellulose, polyester, rayon and glass fibres. The permeable membrane may comprise Ahlstrom ReliaFlow™ 800.

30 Alternatively, advantageously, the permeable membrane comprises Fusion 5, available from GE Healthcare.

35 The permeable membrane on which the sample receiving zone and/or the probe zone and/or the test site are advantageously located may be the same membrane or separate respective membrane. The membrane at the sample receiving portion may comprise a

different material to the material at the probe zone / test site. Alternatively, the material may be the same at the sample receiving portion, the probe zone and the test site.

The permeable membrane may be configured to permit controlled movement of buffer.

5 Advantageously the membrane is permeable in that it allows a reagent (e.g. a buffer) comprising analyte (e.g. a drug molecule or drug metabolite) to pass through the membrane by capillary action. The permeable membrane may comprise nitrocellulose or a similar blotting material. Advantageously the membrane does not allow chromatography effects, i.e. the membrane advantageously does not allow the labelled 10 probe to migrate slower or faster than the analyte such that the labelled probe and analyte separate or do not bind efficiently. In use, a membrane which is configured to allow controlled and predictable movement of buffer increases the accuracy and reliability of the assay and allows results to be reproduced and normalised between samples.

15

In one embodiment, the permeable membrane is treated with hydrophobic glue which provides pores through which a buffer may flow in a pore size dependent manner. Alternatively, or additionally, the permeable membrane comprises a plurality of layers, wherein the layers are optionally separated by a porous glue, which is thought to 20 regulate the flow of buffer from e.g. the buffer receiving portion to the sample receiving portion, thereby giving a desirable rate of flow, the rate maximising the solubilisation of analyte from the sample which is then concentrated at the solvent front.

25

As used herein, the term "*probe*" refers to one or more molecules containing one or more variable analyte binding domain(s). The probe is specific to an analyte (e.g. the drug or drug metabolite which may be present in the sample) and capable of binding to the analyte to form a probe-analyte complex (e.g. an immunocomplex). As used herein, the term "*probe specific to*" refers to a probe which does not bind significantly to any sample components other than the analyte of interest. As used herein, the term "*binding*" refers 30 to an interaction or complexation between a probe and an analyte, resulting in a sufficiently stable complex.

35

The probe may be selected from the group consisting of antibodies, aptamers, and mixtures thereof. Alternatively, advantageously, the probe may be selected from the group consisting of antibodies, aptamers (or other DNA based protein-binding

structures), affimers (or other aminoacid based protein-binding structures), and mixtures thereof. More advantageously the probe is an antibody. The term “*antibody*” includes natural and artificial antibodies as well as divalent antibodies and monovalent antibody Fab and F(ab')₂ fragments. Antibodies bind by means of specific binding sites to specific

5 antigenic determinants or epitopes on antigens, e.g. drugs or drug metabolites.

Advantageously, when the probe is an antibody and the analyte is an antigen of interest, the antibody is specific to the antigen (e.g. the drug or drug metabolite which may be present in the sample) and capable of binding to the antigen to form an immunocomplex (an antibody-antigen complex). As used herein, the term “*antibody specific to*” refers to

10 an antibody which does not bind significantly to any sample components other than the antigen of interest.

The labelled probe may comprise two or more different antibodies. In particular, one antibody may be capable of binding to one antigen and a different antibody may be

15 capable of binding to a different antigen. For example, one antibody may be an antibody capable of binding to morphine and/or a metabolite thereof and another antibody may be an antibody capable of binding to cocaine and/or a metabolite thereof. Providing two or more different antibody is therefore advantageous because more than one analyte, e.g. a drug or drug metabolite, can be detected in the sample, if present. When the labelled probe comprises two or more different antibodies, the different antibodies are labelled with different labels or the same label. Different labels allow the identification and/or quantification of different analytes in the sample, e.g. different drugs and/or their metabolites in the same test site, thereby improving the multiplex capability of the device. When the different antibodies are labelled with the same label, different test sites are

25 used to identify and/or quantify the different analytes in the sample, e.g. different drugs and/or their metabolites.

The probe may comprise divalent antibodies and/or monovalent antibody Fab and F(ab')₂ fragments. A “*divalent antibody*” is an antibody having two binding sites. A

30 divalent antibody is therefore capable of binding to two molecules of an antigen, e.g. a drug and/or a drug metabolite. A “*monovalent antibody Fab and F(ab')₂ fragments*” is an antibody fragment having one binding site. A monovalent antibody Fab or F(ab')₂ fragment is therefore thought to be capable of binding to one molecule of an antigen, e.g. a drug and/or a drug metabolite, leading to increased sensitivity of the device.

Alternatively, advantageously, the probe comprises one or more affimers. Methods of preparing affimers specific to particular targets are known in the art. For example, phage display libraries of potential targets, e.g. drugs of abuse, metabolites thereof, or associated ligands, may be generated through *in vitro* technologies. Affimers may then be generated to display a high affinity binding surface for the specific targets.

In particular, *in vitro* display technologies permits the use of defined selection conditions and provides immediate availability of the sequence encoding the antibody. The amenability of *in vitro* display to high-throughput applications may broaden the prospects for their wider use in basic and applied research. Display libraries can contain up to 2.5×10^{11} members generated from the human repertoire. *In vitro* display technologies therefore offer opportunities to select and characterise those display members which are specific for drugs of abuse and/or metabolites thereof.

The probe is conjugated to a detectable label which provides a means of visualising or detecting the probe, and may comprise a chromogen, a catalyst, a fluorescent compound, a chemiluminescent compound, a colloidal gold, a dye particle, a quantum dot, or a latex particle tagged with a detector reagent such as, for example, a coloured or fluorescent dye. Advantageously, the labelled probe is detectable in radiation having a wavelength of 400 nm to 1 mm. More advantageously, the labelled probe is detectable in radiation having a wavelength of 400 nm to 500 μ m, or from 400 nm to 100 μ m, or from 400 nm to 10 μ m, or from 400 nm to 1 μ m, or from 400 nm to 800 nm, or from 450 nm to 700 nm. The labelled probe may comprise a fluorescently labelled probe. Alternatively, advantageously, the labelled probe may comprise one or more quantum dots.

The probe zone may comprise from 10 pg to 1 μ g of a labelled probe. More advantageously, the probe zone comprises from 10 pg to 500 ng of a labelled probe. More advantageously still, the probe zone comprises from 10 pg to 400 ng, or from 10 pg to 300 ng, or from 10 pg to 250 ng, or from 10 pg to 200 ng, or from 10 pg to 100 ng, or from 10 pg to 1 ng, or from 10 pg to 500 pg, or from 10 pg to 200 pg, of a labelled probe. Alternatively, advantageously, the probe zone comprises from 50 pg to 500 ng, or from 200 pg to 400 ng, or from 500 pg to 300 ng, or from 1 ng to 250 ng, or from 10 ng to 200 ng, or from 20 ng to 150 ng, or from 30 ng to 100 ng of a labelled probe.

Providing a small amount, such as from 10 pg to 100 ng, or from 10 pg to 1 ng, or from 10 pg to 500 pg, or from 10 pg to 200 pg, of labelled probe is thought to increase the sensitivity of the assay, and very small levels of analyte, e.g. drug/drug metabolite, from the sample can be accurately detected. Providing a larger amount, such as 200 ng to 1

5 µg, of a labelled probe allows the detection and quantification of higher levels of analyte in the sample, which may be useful for gross detection levels to identify when a substance, e.g. a drug, has killed someone. It is understood that the amount of labelled probe at the labelled probe zone will vary depending on the affinity of the probe to the analyte. For example, different antibodies may have different affinities, so more or less

10 antibody may be required to provide the optimum levels of sensitivity. For example, mouse antibodies typically have a K_D value of around $10^{-9}M$ while rabbit antibodies typically have a K_D value of around $10^{-11}M$, so the rabbit antibodies have a greater average binding affinity, typically 1 to 2 orders more. It is emphasised that these example values are average K_D values around which there is a normal Gaussian

15 distribution, so some (a small amount) of mouse antibodies will perform as well as rabbit antibodies and vice versa.

The width of the device (for example the width of the substrate or permeable membrane) at the sample receiving portion may be greater than at the probe zone. This is

20 advantageous because, in use, the buffer may pass through a greater area of the sample receiving portion thereby dissolving a larger portion / the entirety of the analyte at the solvent front. The narrowing of the device at or upstream of the probe zone advantageously ensures that the analyte is then further concentrated at the buffer's solvent front when it is presented at the probe zone as a minimal volume of concentrated

25 solute, where the binding of any analyte with the labelled probe takes place. Presenting the highest concentration of analyte at the buffer's solvent front to the labelled probe improves the kinetics of the two entities binding to each other and thereby increases the efficiency, sensitivity and reliability of the assay.

30 Alternatively, advantageously, the width of the device at the sample receiving portion and at the probe zone is substantially the same. This may be advantageous and convenient in the manufacture and packaging of the devices because the devices may be bulk-produced more quickly and easily. Wastage may also be reduced due the shape of the devices (e.g. the substrate or membrane) which may tessellate and, for example, two or

more substantially rectangular devices or membranes may be produced from one piece of rectangular starting material with no or minimal wastage.

Downstream of the probe zone is the test site, the test site comprising a first immobilised capture reagent capable of binding to the labelled probe. The test site may be located on a permeable membrane, advantageously a nitrocellulose permeable membrane.

The test site comprises a first capture reagent which has been immobilised in a particular area of the device, advantageously on the permeable membrane, to "capture" or bind a specific molecule. As used herein, the term "*first immobilised capture reagent*" means that the first capture reagent is attached to or confined within the test site such that lateral flow of fluids across the test site during an assay will not dislodge the first capture reagent. Accordingly, any labelled probe which is not part of a labelled probe-analyte complex (e.g. an immunocomplex) has capacity to bind to the first immobilised capture reagent.

The first immobilised capture reagent may comprise an antigen capable of binding to the labelled probe. Advantageously the antigen is a drug and/or drug metabolite that may also be present as analyte in the sample. The labelled probe may be an antibody and the antigen may be a drug and/or drug metabolite that may also be present as analyte in the sample. Alternatively, advantageously, the labelled probe is an affimer and the antigen is a drug and/or drug metabolite that may also be present as analyte in the sample.

The test site may comprise from 1 ng to 500 ng of the first immobilised capture reagent. More advantageously, the test site comprises from 1 ng to 400 ng, or from 1 ng to 350 ng, or from 1 ng to 300 ng, or from 1 ng to 250 ng, or from 5 ng to 225 ng, or from 10 ng to 200 ng of the first immobilised capture reagent. Providing a small amount, such as from 1 ng to 300 ng, or from 1 ng to 250 ng, or from 1 ng to 250 ng, of first immobilised capture reagent is thought to increase the sensitivity of the assay, and very small levels of analyte, e.g. antigen, from the sample can be accurately detected. Providing a larger amount, such as 350 ng to 500 ng, of first immobilised capture reagent allows the detection of higher levels of analyte in the sample, which may be useful for gross detection levels to identify when a substance, e.g. a drug, has killed someone.

In one embodiment, the first immobilised capture reagent comprises two or more different antigens capable of binding to the labelled probe. In particular, when the labelled probe comprises two or more different antibodies, one antigen may be capable of binding to one antibody and a different antigen may be capable of binding to a different antibody. For example, one antigen may be cocaine or a metabolite thereof and another antigen may be morphine or a metabolite thereof.

5 The device may comprise a plurality of test sites. Each test site may comprise a different first immobilised capture reagent, for example, different immobilised antigens, capable of binding to the labelled probe. In particular, when the labelled probe comprises two or more different antibodies, one antigen capable of binding to one antibody may be immobilised at a first test site, and a different antigen capable of binding to a different antibody may be immobilised at a second test site.

10 15 The test sites may be arranged in series. Alternatively, advantageously, the test sites may be arranged in parallel.

The first capture reagent is immobilised at the test site by conjugation to a linker molecule. The linker molecule-first capture reagent conjugate is immobilised at the test site. Advantageously, the linker molecule-first capture reagent conjugate is immobilised at the test site by hydrophobic and/or electrostatic interaction. The linker molecule may be selected from the group consisting of a protein, a synthetic polymer, a modified sugar molecule, modified DNA and mixtures of two or more thereof. Advantageously, the linker molecule is a protein, which may be a large peptide molecule. More advantageously, the protein comprises Keyhole Limpet Hemacyanin (KLH), Bovine Serum Albumin (BSA), Human Serum Albumin (HSA), Bovine Thyroglobulin (BTG), Horse Radish Peroxidase (HRP), or mixtures of one or more thereof. Most advantageously, the protein comprises Bovine Serum Albumin (BSA). The linker molecule prevents migration of the first capture reagent from the test site.

30 35 When the first capture reagent is immobilised via conjugation to an immobilised protein, advantageously, each immobilised protein molecule is conjugated to 10 to 50, or 15 to 40, or 20 to 35 molecules of first capture reagent. For example, when the protein is BSA and the first capture reagent is morphine, each BSA molecule immobilised at the test site is conjugated to around 30 morphine molecules.

The linker molecule may be provided at a concentration of from 5 µg/ml to 500 µg/ml, or from 10 µg/ml to 250 µg/ml, or from 10 µg/ml to 100 µg/ml and/or the linker molecule is immobilised in a line at the test site in an initial volume of from 50 nl/cm to 1 µl/cm, or

5 from 100 nl/cm to 500 nl/cm, or from 150 nl/cm to 400 nl/cm. Alternatively, advantageously, the linker molecule is provided at a concentration of from 5 µg/ml to 500 µg/ml, or from 10 µg/ml to 250 µg/ml, or from 10 µg/ml to 100 µg/ml and/or the linker molecule is immobilised in a line at the test site in an initial volume of from 500 nl/cm to 1 µl/cm, or from 700 nl/cm to 900 nl/cm, or from 750 nl/cm to 850 nl/cm. Advantageously,

10 when the linker molecule is a protein, and the first capture agent is morphine, the protein is provided at a concentration of from 10 µg/ml to 100 µg/ml, or from 10 µg/ml to 50 µg/ml, or from 20 µg/ml to 40 µg/ml and/or the protein is immobilised in a line at the test site in an initial volume of from 100 to 500 nl/cm. More advantageously, the protein is immobilised in a line at the test site in an initial volume of from 150 to 400 nl/cm, or from

15 200 to 300 nl/cm, or from 225 nl/cm to 275 nl/cm. It is understood that the concentration of protein and the volume per cm at the test site will vary for other first capture reagents and depending on the required assay sensitivity and the number first capture reagents conjugated to each protein molecule.

20 Alternatively, advantageously, when the linker molecule is a protein, and the first capture agent is morphine, the protein is provided at a concentration of from 10 µg/ml to 100 µg/ml, or from 10 µg/ml to 50 µg/ml, or from 20 µg/ml to 40 µg/ml and/or the protein is immobilised in a line at the test site in an initial volume of from 700 to 900 nl/cm, or from 750 nl/cm to 850 nl/cm.

25 The device may further comprise a control site, downstream of the test site, comprising a second immobilised capture reagent capable of binding to the labelled probe, the device being structured to permit movement of a buffer from the test site to the control site. As used herein, the term "*second immobilised capture reagent*" means that the second capture reagent is attached to or confined within the control site such that lateral flow of fluids across the control site during an assay will not dislodge the second capture reagent.

30 In use, as the buffer passes through the control site, the labelled probe dissolved therein will bind to the second immobilised capture reagent whether or not the labelled probe is

35

bound to analyte from the sample. For example, when the sample comprises an antigen, and the labelled probe is a labelled antibody, the second immobilised capture reagent may comprise an immobilised antibody able to bind to the labelled antibody and any immunocomplex comprising the labelled antibody (the antibody-antigen complex).

5 Accordingly, the control site as described herein is advantageous because it indicates that the assay has reliably worked. This is indicated by identifying the label, for example under appropriate radiation at the control site. Identifying the label at the control site after the assay is complete provides proof that the assay has reliably worked i.e. by confirming that the labelled probe has been dissolved by the buffer and has passed
10 through the test site. If the label is not present at the control site after the assay is complete, the assay may not have reliably worked.

The second immobilised capture reagent may comprise an antibody or aptamer, more advantageously an antibody, specific to the labelled probe. Advantageously, the second
15 immobilised capture reagent comprises an antibody, affimer or aptamer, more advantageously an antibody, specific to the labelled probe. As used herein, when an antibody, affimer or aptamer is “*specific*” to the labelled probe, the antibody, affimer or aptamer binds to the labelled probe whether or not the labelled probe has binding sites available.

20 The device may further comprise a normalisation site, the normalisation site comprising an immobilised labelled protein incapable of binding to the labelled probe, the analyte, and any labelled probe-analyte complex, such as an immunocomplex, wherein the immobilised protein in the normalisation site and the probe are labelled with the same label. In effect, the immobilised labelled protein has no affinity for any molecule in the assay and is therefore a constant control against which all other readings in the same assay may be compared and quantitated, thereby making it possible to normalise the data. For example, the normalisation site normalises the data with regard to environmental factors which may differ between assays on different devices. For
25 example, the effect of temperature on binding kinetics can be taken into account. Increased binding rates will be observed with increasing temperature until the proteins start to denature, at which point binding rates will decrease. In one embodiment, the device will monitor the assay temperature and will normalise data via look-up tables with reference to the constant fluorescent signal in the normalisation site. Furthermore, for
30 example, when the probe and immobilised protein at the normalisation site are
35

fluorescently labelled, environmental factors such as temperature-dependent quenching of the fluorophore can be taken into account.

The device may further comprise a sink downstream of the test site and/or the control

5 site, the device being configured to permit movement of a buffer from the test site and/or the control site to the sink, wherein the sink is configured to prevent movement of the buffer from the sink. Advantageously, the sink serves to “pull” any fluids / buffer added to the device for the duration of the assay by absorbing the fluids / buffer.

Advantageously, the sink is of sufficient capacity and absorption ability to ensure that

10 fluids / buffer do not backflow upstream to the test site and/or control site, which may compromise the assay results. Advantageously, the sink has a volume of from 100 to 500 µl. More advantageously, the sink has a volume of from 100 to 400 µl, or from 100 to 300 µl, or from 100 to 250 µl, or from 100 to 200 µl. Alternatively, advantageously, the sink has a volume of from 125 to 300 µl, or from 150 to 250 µl, or from 175 to 215 µl.

15 Alternatively, advantageously, the sink has a volume of from 150 to 550 µl, or from 200 to 500 µl, more advantageously from 250 to 400 µl, or from 300 to 375 µl, most advantageously from 325 to 350 µl. Advantageously the sink comprises an absorbent and/or hydrophilic material. Advantageously, the sink comprises one or more of high density cellulose, glass fibre/cellulose mix and cotton linter/fibres.

20

The device may further comprise a backing layer. Advantageously, the backing layer serves as a physical support or a base upon which the sample receiving portion, the labelled probe zone, the test site, and optionally the control site and/or the normalisation site and/or the sink, are mounted. Advantageously, the backing layer comprises a

25 plastic strip such as, for example, polystyrene. The sample receiving portion, the labelled probe zone, the test site, and optionally the control site and/or the normalisation site and/or the sink may be mounted to the backing layer by an adhesive, advantageously a hydrophobic adhesive. Advantageously, the permeable membrane(s), backing layer and any adhesive do not scatter light or fluoresce at the wavelengths used to identify the one or more labels, thereby improving the reliability of the assay.

30

The device may further comprise a fingerprint pattern receiving zone, wherein the fingerprint pattern receiving zone is separate to the sample receiving zone.

Advantageously, the fingerprint pattern receiving zone comprises a different material to

35 the sample receiving zone. Advantageously, the fingerprint pattern receiving zone

comprises glass and/or plastic and/or silicon wafer. The fingerprint pattern receiving zone is advantageously provided so that the sample donor (which is advantageously another fingerprint) can be positively identified before, during, or after the assay.

5 The lateral flow device may be housed within a cassette defining an aperture for receiving a sample on the sample receiving portion. Advantageously, the aperture for receiving a sample is configured such that the sample is deposited onto a pre-determined area of the sample receiving portion. Advantageously, the aperture is substantially oblong, substantially circular or substantially oval. Advantageously, the pre-determined area of the sample receiving portion is 60 to 100% of the area of the fingerprint of an average adult human. More advantageously, the pre-determined area of the sample receiving portion is 70 to 100%, or from 80 to 100%, or from 90 to 100%, of the area of the fingerprint of an average adult human. Such a configuration of the aperture provides more normalised results from sample to sample.

15 The lateral flow device may be housed within a cassette defining a window for viewing a test signal and/or a control signal and/or a normalisation signal. The window is positioned above the test site and/or the control site and/or the normalisation site, to permit visualisation or detection of the test site and/or the control site and/or the normalisation site. The window is advantageously formed of a transparent polymer material. The results of the assay may be viewed through the window by eye, a detector, or reader system. Non-limiting examples of such devices include spectrophotometers, reflectance readers, luminometers, fluorometers, photodetectors or photomultiplier tubes, scintillation counters, photodiodes, photodiode arrays and charge-coupled devices.

In one embodiment, advantageously, the lateral flow device is housed within a cassette defining an aperture for receiving a buffer upstream of the sample receiving portion.

30 The present disclosure may further provide a method for analysing a sample comprising from 0.1 pg to 1 µg of analyte, the method comprising:

(a) providing a sample, the sample containing or not containing from 0.1 pg to 1 µg of an analyte of interest;

35 (b) dissolving at least a portion of the sample in a buffer to form a dissolved sample solution;

(c) contacting at least a portion of the dissolved sample solution with a probe zone comprising a labelled probe to dissolve at least a portion of the labelled probe and allow the labelled probe to bind with the analyte, where present, in the portion of the dissolved sample solution to form a labelled probe-analyte complex;

5 (d) passing the labelled probe and/or labelled immunocomplex through a test site comprising a first immobilised capture reagent capable of binding to the labelled probe;

(e) determining whether or not the amount of analyte, if any, in the sample exceeds a threshold value by detecting the amount of labelled probe in the test site.

10 The labelled probe-analyte complex, formed in step (c) if analyte is present in the sample, is understood to have no binding sites available to the first immobilised capture reagent. Therefore, the first immobilised capture reagent is capable of binding to the labelled probe, and incapable of binding to the labelled probe-analyte complex.

15 The sample may comprise sweat, advantageously eccrine sweat. More advantageously, the sample comprises finger-sweat and/or palm-sweat and/or toe-sweat. Most advantageously, the sample comprises finger-sweat.

20 The sample may be provided in step (a) on a sample receiving portion of a lateral flow device, the device further comprising:

the probe zone downstream of the sample receiving portion;

the test site, downstream of the probe zone, comprising a first immobilised capture reagent capable of binding to the labelled probe;

25 the device being configured to permit movement of a buffer from the sample receiving portion to the probe zone and from the probe zone to the test site.

The sample may be provided directly to the sample receiving portion, i.e. the sample is advantageously not subjected to any process steps between obtaining the sample and providing the sample to the sample receiving portion. Advantageously, the sample is not suspended in a buffer before being provided to the sample receiving portion.

The sample provided in step (a) may be substantially dry, such that the sample comprises insufficient liquid to move from the sample receiving zone to the probe zone, for example by capillary action.

The sample may be provided in step (a) as a fingerprint, the fingerprint comprising sweat deposited as an impression of a finger's ridge pattern.

Step (b) may be carried out by providing the buffer upstream of the sample receiving

5 portion and passing the buffer through the sample receiving portion.

The sample may be dissolved in step (b) such that the sample is contacted with the probe zone at the solvent front in step (c).

10 The buffer may be provided in a volume of from 100 to 500 μ l. More advantageously, the buffer is provided in a volume of from 100 to 450 μ l, or from 100 to 400 μ l, or from 100 to 350 μ l, or from 100 to 300 μ l, or from 100 to 250 μ l, or from 100 to 200 μ l.

Alternatively, advantageously, the buffer is provided in a volume of from 125 to 300 μ l, or from 150 to 250 μ l, or from 175 to 215 μ l of buffer. Alternatively, advantageously, the
15 buffer is provided in a volume of from 150 to 550 μ l, or from 200 to 500 μ l, more advantageously from 250 to 400 μ l, or from 300 to 375 μ l, most advantageously from 325 to 350 μ l. Larger volumes of buffer may be advantageous by helping to wash away any unbound labelled probe from the test site and/or the control site and prevent false readings.

20 The buffer to sample volume ratio may be from 50:1 to 1,000 to 1, more advantageously from 100:1 to 1,000:1, or from 200:1 to 1,000:1, or from 300:1 to 1,000:1, or from 400:1 to 1,000:1. More advantageously still, the buffer to sample volume ratio is from 500:1 to 1,000:1.

25 The buffer composition may be as described above in relation to the lateral flow device of the present disclosure.

30 The sample may comprise from 0.1 pg to 1 μ g of analyte. More advantageously, the sample comprises from 0.1 pg to 500 ng, or from 0.1 pg to 200 ng, or from 0.1 pg to 100 ng, or from 0.1 pg to 50 ng, or from 0.1 pg to 10 ng, or from 0.1 pg to 5 ng, or from 0.5 pg to 4 ng, or from 0.5 pg to 3 ng, or from 1 pg to 2 ng, or from 1 pg to 1 ng, or from 1 pg to 500 pg, or from 1 pg to 400 pg, or from 1 pg to 300 pg, or from 2 pg to 250 pg, or from 3 pg to 225 pg, or from 5 pg to 200 pg of analyte. Alternatively, the sample comprises

from 10 pg to 2 ng, or from 20 pg to 1.5 ng, or from 30 pg to 1.25 ng, or from 40 pg to 1 ng, or from 50 pg to 500 pg, or from 50 pg to 300 pg, or from 50 pg to 200 pg of analyte.

The analyte, if present, may comprise a drug metabolite and/or a drug. Drugs that may

5 be detected using the method of the present disclosure, if suitable antibodies are available, include, but are not limited to:

A. ANABOLIC AGENTS. These include, but are not limited to:

- 10 1. Anabolic Androgenic Steroids (AAS)
 - a. Exogenous* AAS, including:
1-androstendiol (5 α -androst-1-ene-3 β ,17 β -diol); 1-androstendione (5 α -androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17 α -ethynyl-17 β -hydroxyandrost-4-eno[2,3-d]isoxazole);
15 dehydrochlormethyltestosterone (4-chloro-17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one); desoxymethyltestosterone (17 α -methyl-5 α -androst-2-en-17 β -ol); drostanolone; ethylestrenol (19-nor-17 α -pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17 β -hydroxy-17 α -methyl-5 α -androstano[2,3-c]furazan);
20 gestrinone; 4-hydroxytestosterone (4,17 β -dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one); methandriol; methasterone (2 α , 17 α -dimethyl-5 α -androstane-3-one-17 β -ol); methyldienolone (17 β -hydroxy-17 α -methylestra-4,9-dien-3-one); methyl-1-testosterone (17 β -hydroxy-17 α -methyl-5 α -androst-1-en-3-one); methylnortestosterone (17 β -hydroxy-17 α -methylestr-4-en-3-one);
25 methyltrienolone (17 β -hydroxy-17 α -methylestra-4,9,11-trien-3-one); methyltestosterone; mibolerone; nandrolone; 19-norandrostenedione (estr-4-ene-3,17-dione); norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanazol ([3,2-c]pyrazole-5 α -etioallocholane-17 β -tetrahydropyranol); quinbolone; stanozolol; stenbolone; 1-
30 testosterone (17 β -hydroxy-5 α -androst-1-en-3-one); tetrahydrogestrinone (18 α -homo-pregna-4,9,11-trien-17 β -ol-3-one); trenbolone, and other substances with a similar chemical structure or similar biological effect(s).
- 35 b. Endogenous** AAS:

androstenediol (androst-5-ene-3 β ,17 β -diol); androstenedione (androst-4-ene-3,17-dione); dihydrotestosterone (17 β -hydroxy-5 α -androstan-3-one); prasterone (dehydroepiandrosterone, DHEA); testosterone and the following metabolites and isomers:

5 5 α -androstane-3 α ,17 α -diol; 5 α -androstane-3 α ,17 β -diol; 5 α -androstane-3 β ,17 α -diol; 5 α -androstane-3 β ,17 β -diol; androst-4-ene-3 α ,17 α -diol; androst-4-ene-3 α ,17 β -diol; androst-4-ene-3 β ,17 α -diol; androst-5-ene-3 α ,17 β -diol; androst-5-ene-3 β ,17 α -diol; 4-androstenediol (androst-4-ene-3 β ,17 β -diol); 5-androstenedione (androst-5-ene-3,17-dione); epi-dihydrotestosterone; 3 α -hydroxy-5 α -androstan-17-one; 3 β -hydroxy-5 α -androstan-17-one; 19-norandrosterone; 19-noretiocholanolone.

* *“exogenous” refers to a substance which is not ordinarily capable of being produced by the body naturally.*

15 ** *“endogenous” refers to a substance which is capable of being produced by the body naturally.*

2. Other Anabolic Agents. These include, but are not limited to:

20 Clenbuterol, tibolone, zeranol, zilpaterol.

B. Hormones. These include, but are not limited to:

1. Erythropoietin (EPO);
2. Growth Hormone (hGH), Insulin-like Growth Factors (e.g. IGF-1),
25 Mechano Growth Factors (MGFs);
3. Gonadotrophins (LH, hCG), prohibited in males only;
4. Insulin;
5. Corticotrophins.

30 C. BETA-2 AGONISTS, including their D- and L-isomers.

D. AGENTS WITH ANTI-ESTROGENIC ACTIVITY. These include, but are not limited to:

1. Aromatase inhibitors including, but not limited to, anastrozole, letrozole, aminoglutethimide, exemestane, formestane, testolactone.

2. Selective Estrogen Receptor Modulators (SERMs) including, but not limited to, raloxifene, tamoxifen, toremifene.
3. Other anti-estrogenic substances including, but not limited to, clomiphene, cyclofenil, fulvestrant.

5

E. DIURETICS AND OTHER MASKING AGENTS. These include, but are not limited to: Diuretics*, epitestosterone, probenecid, alpha-reductase inhibitors (e.g. finasteride, dutasteride), plasma expanders (e.g. albumin, dextran, hydroxyethyl starch) and other substances with similar biological effect(s).

10

Diuretics include:

acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene, and other substances with a similar chemical structure or similar biological effect(s).

15

F. AGENTS FOR THE ENHANCEMENT OF OXYGEN TRANSFER. These include, but are not limited to:

1. Autologous, homologous or heterologous blood or red blood cell products of any origin.
2. perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products).

25

G. STIMULANTS (including both their (D- & L-) optical isomers where relevant). These include, but are not limited to:

Adrafinil, adrenaline**, amfepramone, amiphenazole, amphetamine, amphetaminil, benzphetamine, benzylpiperazine, bromantan, cathine***, clobenzorex, cocaine, cropropamide, crotetamide, cyclazodone, dimethylamphetamine, ephedrine****, etamivan, etilamphetamine, etilefrine, famprofazone, fenbutrazate, fencamfamin, fencamine, fenetylline, fenfluramine, fenproporex, furfenorex, heptaminol, isometheptene, levmethamphetamine, meclofenoxate, mefenorex, mephentermine, mesocarb, methamphetamine (D-), methylenedioxymethamphetamine, methylenedioxymethamphetamine, pmethylamphetamine, methylephedrine****, methylphenidate, modafinil,

30

35

5 nikethamide, norfenefrine, norfenfluramine, octopamine, ortetamine, oxilofrine, parahydroxyamphetamine, pemoline, pentetrazol, phendimetrazine, phenmetrazine, phenpromethamine, phentermine, 4-phenylpiracetam (carphedon), prolintane, propylhexedrine, selegiline, sibutramine, strychnine, tuaminoheptane and other substances with a similar chemical structure or similar biological effect(s).

H. NARCOTICS These include, but are not limited to:

10 Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, codeine, oxycodone, oxymorphone, pentazocine, pethidine.

I. CANNABINOIDS These include, but are not limited to:

15 Hashish, marijuana.

J. GLUCOCORTICOSTEROIDS

K. ALCOHOL (ethanol).

20 L. BETA-BLOCKERS These include, but are not limited to:

acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol.

25 M. AMPHETAMINES. These include, but are not limited to:

methamphetamine and MDMA (3,4-methylenedioxy-N-methylamphetamine); LSD (lysergic acid diethylamide); PCP (Phencyclidine), ketamine and derivatives;

30 N. ALKALOIDS AND THEIR DERIVATIVES. These include, but are not limited to: nicotine, cocaine, ephedrine, mescaline; opium alkaloids (opioids), including morphine and codeine, and semi-synthetic opioids such as diamorphine (heroin); tryptamine alkaloids such as dimethyltryptamine and alpha-methyltryptamine;

35 O. BENZODIAZEPINES. These include, but are not limited to:

Alprazolam, Diazepam, Lorazepam, Clonazepam, Temazepam, Oxazepam, Flunitrazepam, Triazolam, Chlordiazepoxide, Flurazepam, and Nitrazepam, and nonbenzodiazepines, including Imidazopyridines, Pyrazolopyrimidines, Cyclopyrroles.

5

P. GHB (gamma-Hydroxybutyric acid) and derivatives.

The method and device of the present disclosure may be used to detect metabolites of the drugs mentioned above, for which antibodies are available. If an antibody for a 10 particular target substance, such as a drug or its metabolite, is not available commercially, the person skilled in the art could readily raise such an antibody using known techniques.

The analyte may be one or more of morphine, cocaine, cannabis, benzodiazepine, 15 amphetamine, methadone, buprenorphine and/or metabolites of one or more thereof. More advantageously, the analyte is one or more of morphine, cocaine, and metabolites of one or more thereof.

Alternatively, advantageously, the analyte may be one or more of morphine, cocaine, 20 cannabis, benzodiazepine, amphetamine, methadone, buprenorphine, codeine, dihydrocodeine, 6-methylacetyl morphine (6-MAM), alcohol and/or metabolites of one or more thereof, including metabolites of cocaine such as benzoylecgonine, cocaethylene, ecgonine ethyl ester, ecgonine methyl ester and norcocaine, and metabolites of alcohol such as ethylglucuronide. More advantageously, the analyte is one or more of morphine, 25 cocaine, codeine, alcohol and metabolites of one or more thereof.

Advantageously, the analyte is cocaine. Alternatively, advantageously, the analyte is morphine. Alternatively, advantageously, the analyte is cannabis. Alternatively, 30 advantageously, the analyte is amphetamine. Alternatively, advantageously, the analyte is methamphetamine. Alternatively, advantageously, the analyte is benzodiazepine. Alternatively, advantageously, the analyte is methadone.

Alternatively, advantageously, the analyte metabolite is a cocaine metabolite, selected from one or more of benzoylecgonine, cocaethylene, ecgonine ethyl ester, ecgonine 35 methyl ester and norcocaine. More advantageously, the analyte is benzoylecgonine.

Alternatively, advantageously, the analyte metabolite is an alcohol metabolite. More advantageously, the analyte metabolite is ethylglucuronide.

5 The method may further comprise:

(f) passing the labelled probe and/or the labelled probe-analyte complex through a control site comprising a second immobilised capture reagent capable of binding to the labelled probe and to the labelled probe-analyte complex; and

(g) determining whether or not the test result is reliable by detecting or not

10 detecting the labelled probe and/or the labelled probe-analyte complex in the control site.

The labelled probe may be detectable in radiation having a wavelength of 400 nm to 1 mm, and step (e) and/or step (g) is carried out by illuminating the test site and/or the first control site with radiation having a wavelength of 400 nm to 1 mm to show the labelled 15 probe and/or labelled probe-analyte complex, if present.

The method may further comprise:

(h) illuminating a normalisation site with radiation having a wavelength of 400 nm to 1 mm, measuring the signal intensity of the normalisation site and comparing said 20 signal intensity to the signal intensity detected at the test site and/or the control site;

wherein the normalisation site comprises an immobilised labelled protein incapable of binding to the labelled probe, the analyte, and any labelled probe-analyte complex comprising the labelled probe and the analyte; and

25 wherein the immobilised labelled protein and the labelled probe are labelled with the same label.

The method may further comprise obtaining a fingerprint pattern on a fingerprint pattern receiving zone, wherein the fingerprint pattern receiving zone is separate to the sample receiving portion but is housed within the same device. Advantageously, the method 30 further comprises scanning and/or recording the fingerprint pattern.

The method is fast, accurate and inexpensive due to the reduced volume of sample and reagents (i.e. nanolitres / microlitres), inexpensive and disposable materials, and minimal testing steps. Fluid flow manipulation is governed by capillary action through the test strip. Fluid handling, separation and detection functionalities are conveniently integrated 35

within the method. Samples may thus be processed rapidly in minutes, compared to current time-consuming technologies, for example, liquid chromatography-tandem mass spectrometry, radio-immunoassays, solvent extraction and HPLC, which require a high degree of proficiency, extensive training and expensive equipment. The device and

5 method therefore reduces costs for both the patient and e.g. healthcare systems because the results may be obtained within minutes of performing the test, either at home or at a point-of-care location. Advantageously, the method is carried out in from one to ten minutes.

10 The present disclosure may provide a method of preparing the lateral flow device as described herein, comprising:

providing a fingerprint receiving portion to a permeable membrane;
applying a labelled probe to the permeable membrane to create a probe zone;
applying to the permeable membrane and immobilising thereon a first capture

15 reagent capable of binding to the labelled probe to create a test site.

The lateral flow device may be fabricated using techniques known to those skilled in the art. The labelled probe zone is pre-treated with labelled probe by dispensing or dipping, followed by drying. The first and optionally second capture reagents at the test and

20 control sites can be immobilised using several methods well known to those skilled in the art including, for example, direct adsorption and covalent attachment. Blocking of non-specific binding may be achieved by coating the surface of the device, for example the permeable membrane, with blocking buffers such as for example, bovine serum albumin and/or detergent, followed by drying. The sample receiving portion may also be pre-treated to filter out particulates, bind sample components which might interfere with the assay, or disrupt the sample to release the target analyte. The device may be optionally be assembled on cards, with the sample receiving portion, the labelled probe zone, the test site, and optionally the control site and/or the normalisation site and/or the sink, being mounted onto a backing layer using an appropriate adhesive. The cards may then

25

30 be cut into individual devices or strips.

The method may further comprise providing a buffer receiving portion to the permeable membrane and optionally a reservoir of buffer to the substrate.

The method may further comprise applying to the permeable membrane and immobilising thereon a second capture reagent capable of binding to the labelled probe to create a control site.

5 The method may further comprise applying to the permeable membrane and immobilising thereon a labelled protein to create a normalisation site, wherein the labelled protein is incapable of binding to the labelled probe.

10 Advantageously, 10 pg to 1 µg of labelled probe is applied to the permeable membrane to create the probe zone. More advantageously, from 10 pg to 500 ng, or from 10 pg to 400 ng, or from 10 pg to 300 ng, or from 10 pg to 250 ng, or from 10 pg to 200 ng, or from 10 pg to 100 ng, or from 10 pg to 1 ng, or from 10 pg to 500 pg, or from 10 pg to 200 pg, of labelled probe is applied to the permeable membrane to create the probe zone. Alternatively, advantageously, from 50 pg to 500 ng, or from 200 pg to 400 ng, or 15 from 500 pg to 300 ng, or from 1 ng to 250 ng, or from 10 ng to 200 ng, or from 20 ng to 150 ng, or from 30 ng to 100 ng, is applied to the permeable membrane to create the probe zone.

20 The present disclosure may provide a kit for the analysis of a sample, comprising:
the device as described herein; and
a fluorescence, ultraviolet, infrared and/or a far infrared detector.

25 The present disclosure may provide a method of dissolving at least a portion of a bodily fluid, the method comprising contacting a bodily fluid with a buffer, the buffer comprising:
a water miscible organic solvent;
a surfactant, advantageously a detergent; and
a buffering agent.

30 It may be advantageous that the buffer comprises all of the three components mentioned above. The buffer may be effective at solubilising at least a portion of a bodily fluid such that the portion of bodily fluid can then be analysed using one or more reagents or techniques. The buffer's individual components and preferred or available amounts thereof are described in further detail below.

Water miscible solvents are known in the art. The water miscible organic solvent may comprise one or more of ethanol, methanol and tetrahydrofuran. The buffer may comprise 10 to 30 v/v % water miscible organic solvent. More advantageously, the buffer comprises from 15 to 25 v/v %, or from 18 to 22 v/v % water miscible organic solvent. The water miscible organic solvent helps hydrophilic and hydrophobic molecules partition in water.

Surfactants are known in the art and may include any molecule that forms micelles, for example amphiphilic molecules. The surfactant comprises one or more of Tween-20, Tween 80, Triton X-100, tetraoctyl ammonium bromide, Polyethylene glycol (PEG) and octanoic acid. Alternatively, advantageously, the surfactant comprises one or more of Tween-20, Tween 80, Triton X-100, Triton X-114, tetraoctyl ammonium bromide, Polyethylene glycol (PEG) and octanoic acid. More advantageously, the surfactant comprises one or more of Tween-20, Tween 80, Triton X-100 and tetraoctyl ammonium bromide. Alternatively, more advantageously, the surfactant comprises one or more of Tween-20, Tween 80, Triton X-100, Triton X-114 and tetraoctyl ammonium bromide. Advantageously, the buffer comprises 0.1 to 0.15 w/v % surfactant. More advantageously, the buffer comprises 0.11 to 0.14 w/v %, or 0.12 to 0.13 w/v % surfactant. The surfactant, advantageously a detergent, is thought to aid release of analyte, e.g. drugs and/or drug metabolites, from the bodily fluid. The surfactant molecules may be present in a concentration above their critical micelle concentration (CMC). The micelles thus present within the surfactant are advantageously able to act as a carrier for any hydrophobic analyte, e.g. drugs and drug metabolites, and allow presentation of said analyte during analysis undertaken on the bodily fluid.

Suitable buffering agents are known in the art. The buffering agent may comprise one or more of HEPES, Tris, TRIZMA and phosphate buffer. Advantageously, the buffer comprises 5 to 100 mM buffering agent. More advantageously, the buffer comprises 5 to 75 mM, or 5 to 50 mM, or 5 to 25 mM, or 5 to 15 mM, or 5 to 10 mM, or 6 to 9 mM, or 7 to 8 mM buffering agent. The buffering agent is thought to assist in increasing the solubility of any analyte in the bodily fluid, e.g. drugs and/or drug metabolites, based on their pKa and PI values.

The buffer may further comprise one or more anti-oxidants. Suitable anti-oxidants include ethyl acetate, methyl anthranilate, 2-pentyl butyrate and ethyl butyrate. Anti-

oxidants may help to prevent the oxidation of any analyte or metabolite thereof and any organic material in the bodily fluid, such as fingerprint lipids. This is desirable because, if the analyte and/or metabolite thereof is oxidised, its properties (e.g. its charge) may change. Any changes in physical or chemical properties could interfere with analysis of

5 the analytes or metabolites

The buffer may further comprise an emulsifier. Advantageously, the emulsifier is selected from deoxycholate, cholesterol and combinations thereof. More advantageously, the emulsifier is deoxycholate. Without wishing to be bound by theory,

10 an emulsifier such as deoxycholate helps to present any analyte or metabolites thereof in the bodily fluid during analysis. This is thought to be achieved by the emulsifier helping to 'open up' any lipid structures in the sample encourage any hydrophobic analyte or metabolite to be available for binding.

15 In one embodiment, the buffer further comprises a salt. Advantageously, the salt is selected from NaCl, KCl or a mixture thereof.

The bodily fluid may comprise finger-sweat.

20 The present disclosure may provide a lateral flow device for detecting from 0.1 pg to 1 µg of analyte in a sample.

25 When introducing elements of the present disclosure or the preferred embodiments(s) thereof, the articles "a", "an", "the" and "said" are intended to mean that there are one or more of the elements. The terms "comprising", "including" and "having" are intended to be inclusive and mean that there may be additional elements other than the listed elements.

30 The foregoing detailed description has been provided by way of explanation and illustration, and is not intended to limit the scope of the appended claims. Many variations in the presently preferred embodiments illustrated herein will be apparent to one of ordinary skill in the art, and remain within the scope of the appended claims and their equivalents.

35 These and other aspects of the disclosure will now be described with reference to the accompanying Figures, in which:

Figure 1: is a diagram of the lateral flow device according to one embodiment of the present disclosure.

5 **Figure 2:** is a photograph of lateral flow test strips obtained as set out in Example 1.

Figures 3 to 6: are images of lateral flow test strips obtained as set out in Example 2.

10 **Figures 7 to 10:** are images of lateral flow test strips obtained as set out in Example 3.

15 **Figure 11:** is a graph showing the results of a comparison between a nitrocellulose lateral flow assay vs. plate assay.

20 **Figure 12:** is a diagram showing the steps of a ten minute assay using the device of the present disclosure.

Figure 13: is a graph showing results of the lateral flow tests on fingerprint samples taken from people testing positive for morphine by oral fluid analysis.

25 **Figure 14:** is a graph showing results of the lateral flow tests on fingerprint samples taken from people testing negative for morphine by oral fluid analysis.

Figure 15: is a graph showing results of the lateral flow tests on fingerprint samples taken from people testing positive for BZE by oral fluid analysis.

30 **Figure 16:** is a graph showing results of the lateral flow tests on fingerprint samples taken from people testing negative for BZE by oral fluid analysis.

The following non-limiting examples further illustrate the present disclosure.

EXAMPLES

The present disclosure will now be described in relation to several examples.

Example 1: Homogeneously distributed dried drug over the Sample Receiving Portion is concentrated at the solvent front when solvent is applied upstream of the deposited sample.

5 Solution set 1 (Set 1): Morphine was dissolved in methanol at 0 to 900 pg per 100 μ l of solvent.

Solution set 2 (Set 2): Morphine was dissolved in fingerprint solubilisation buffer at 0 to 900pg per 100 μ l of solvent.

10 A series of lateral flow strips of the present disclosure were set up having two test sites and no control sites. The volume of the sample receiving portion is around 110 μ l.

15 Each test line (each test site) is BSA-Morphine (40 μ g/ml) conjugate applied at 0.25 μ l / cm.

The labelled probe zone is provided with 50ng labelled antibody / zone in loading buffer
(100mM Sucrose in
10mM PB pH 7.42, 1% (w/v) Tween-80).

20 100 μ l of solution from Set 1 were applied to the sample receiving portion of a series of lateral flow strips and then dried.

25 100 μ l of solutions from Set 2 were applied to the sample receiving portion of a second series of lateral flow strips and while still wet, fresh fingerprint solubilisation buffer was used to chase the liquid through the lateral flow strip by applying the buffer to the bottom edge of the pad i.e. upstream of the sample receiving portion. A similar application of fingerprint solubilisation buffer to the pads containing dried Morphine was performed in parallel.

30 Set 2 represents what would happen if solvent were applied directly to the fingerprint, similar to sample application to sample pad areas of conventional test strips. Set 1 shows what happens when buffer is applied upstream of the print. Here buffer slowly wets the fingerprint area, solubilising the drug / drug metabolites as it advances

downstream the lateral flow strip, incrementally concentrating the drug material at the buffer solvent front.

The assay results are shown in Figure 2. The data clearly demonstrates that the drug in
5 the membranes from Set 1 has been concentrated with respect to similar levels found in Set 2.

The method used by set 2 (similar to a typical lateral flow approach) is not sensitive
enough and is unable to detect the lowest levels of drug found on the fingerprint which
10 would indicate a person is just above the legal cut-off. The present disclosure clearly
detects the drug / metabolite at 150pg per sample.

Testing using the set 2 format only appears to detect the presence of drug / metabolite
between 750 to 900pg which is well above the cut-off and of no use for routine testing,
15 as the value is too high.

Example 2:

Fingerprints were collected from three patients on a variety of sample receiving portion
20 materials on lateral flow strips of the present disclosure having two test sites and no
control sites.

The saliva opiate levels of the patients were confirmed by LGC as follows:

Donor 04745007: Negative

25 Donor 04745008: >1700ng/ml of opiates – Very high levels

Donor 04745009: >10ng/ml of 6-acetyl morphine (opiate heroin marker) – level 2.5x Cut-off value

Lateral flow assays were run by applying the solubilisation buffer of Example 1. Images
30 of the resulting test lines were captured by illumination of the samples for 5 seconds
each.

The results are shown in Figures 3 to 6.

For each of the four substrates tested, clear inhibition (opiate detection) is seen for sample 04745008. Partial inhibition is observed for sample 04745009 which is in line with low levels of metabolite. Use of a calibration curve would allow quantitation of this value.

5

The results show that the sample receiving portion may comprise any material that does not bind the analyte (drug or drug metabolite) being investigated and allows buffer to migrate through it slowly in order to collect and concentrate the metabolite at the solvent front.

10

Example 3: Evidence for varying the assay sensitivity range

15

Samples having 0 pg, 150 pg, 300 pg and 450 pg of morphine were provided on sample receiving portion of lateral flow strips of the present disclosure having two test sites and no control sites.

Assays were run, varying the amount of labelled antibody and/or amount of antigen in the test sites.

20

Figs 7 to 10 show the results obtained.

Cut-off values for opiates may be around 90 pg per print. Similar studies have been done for the cocaine metabolite BZE, the cut-off value for which is around 68 pg per print.

25

The results show that the lower the amount of antibody, the more sensitive the assay is, which is useful for detecting low levels of drugs and/or drug metabolites. Also, the lower the amount of immobilised antigen in the test sites, the more sensitive the assay is.

30

Example 4: Comparison between a nitrocellulose lateral flow assay vs. plate assay

- A Plate was coated with 50 µg/ml BSA-MOR (4.7 mg/ml): at 4°C, overnight:
 - 5.3 µl stock + 495 µl 100 mM bicarbonate buffer pH 9.5 (diluted from 1077RD)

- After incubation, the coated wells were washed 3x with 100 μ l PBST (from 1402RD, diluted to 1x with H₂O)
- A series of dilution of MOR was prepared:
 - Stock solutions: 1 mg/ml
 - Stock was diluted to 10 μ g/ml: 10 μ l stock + 990 μ l PBST (from 1402RD, diluted to 1x with H₂O) The 10 μ g/ml solution was further diluted to 100 ng/ml : 10 μ l 10 μ g/ml + 990 μ l PBST (from 1402RD, diluted to 1x with H₂O)
 - A 4-fold dilution series was prepared starting with 100 ng/ml:
 - 25 ng/ml: 50 μ l 100 ng/ml + 150 μ l PBST (from 1402RD, diluted to 1x with H₂O)
 - 6.25 ng/ml: 50 μ l 100 ng/ml + 150 μ l PBST (from 1402RD, diluted to 1x with H₂O)
 - 1.56 ng/ml: 50 μ l 100 ng/ml + 150 μ l PBST (from 1402RD, diluted to 1x with H₂O)
 - 0.39 ng/ml: 50 μ l 100 ng/ml + 150 μ l PBST (from 1402RD, diluted to 1x with H₂O)
 - 0.09 ng/ml: 50 μ l 100 ng/ml + 150 μ l PBST (from 1402RD, diluted to 1x with H₂O)
 - 0.02 ng/ml: 50 μ l 100 ng/ml + 150 μ l PBST (from 1402RD, diluted to 1x with H₂O)
 - 0.006 ng/ml: 50 μ l 100 ng/ml + 150 μ l PBST (from 1402RD, diluted to 1x with H₂O)
 - 0.0015 ng/ml: 50 μ l 100 ng/ml + 150 μ l PBST (from 1402RD, diluted to 1x with H₂O)
 - 0.0004 ng/ml: 50 μ l 100 ng/ml + 150 μ l PBST (from 1402RD, diluted to 1x with H₂O)
 - 0.0001 ng/ml: 50 μ l 100 ng/ml + 150 μ l PBST (from 1402RD, diluted to 1x with H₂O)
 - Control: PBST (from 1402RD, diluted to 1x with H₂O)
- rabbit anti-MOR-FITC antibody dilution was prepared:
 - 1 μ l stock (mAbF-MOR-004-006; 0.5 mg/ml) + 99 μ l extraction buffer 1420RD or PBST (from 1402RD, diluted to 1x with H₂O)

- 18 µl of MOR dilution was incubated with 2 µl of rabbit anti-MOR-FITC and incubated at room temp. for 4 min
- 10 µl from these reactions were transferred into the BSA-MOR coated wells and incubated for 4 min at room temperature
- 5 • After incubation, the wells were washed 3x with 100 µl PBST (from 1402RD, diluted to 1x with H₂O)
- empty wells were filled with 10 µl PBST (1402RD) and the fluorescence was measured in a plate reader with a 485 nm excitation filter and a 535 nm emission filter for 1 s
- 10 • experiment with PBST as solvent: concentration-dependent inhibition; sensitivity: approx. 0.1 – 0.39 ng/ml

The results are shown in Figure 11, a dose response curve which shows the detection of morphine in the 4pg-225pg range.

15

Example 5:

Oral fluid was taken from 184 people and the fluid analysed for the presence of morphine and/or metabolites thereof. Positive samples were shown to comprise morphine and/or 20 metabolites thereof. Negative samples were shown to not comprise morphine and/or metabolites thereof. There were 92 positive samples and 92 negative samples

Fingerprint samples were taken from the same people and the lateral flow device as described herein was used to test for the presence of morphine or metabolites thereof. 25 The cut-off point for detecting the presence of morphine in the fingerprint was 180 pg, i.e. the fingerprint samples shown to comprise 180 pg or more of morphine and/or metabolites thereof were deemed positives, whilst the samples shown to comprise less than 180 pg or more of morphine and/or metabolites thereof were deemed negatives.

30 The results were compared to the results obtained via oral fluid analysis. A test showing the presence of morphine and/or metabolites thereof which agreed with the oral fluid analysis was deemed to be a true positive (TP). A test showing the presence of morphine and/or metabolites thereof which did not agree with the oral fluid analysis was deemed to be a false positive (FP). A test not showing the presence of morphine and/or

metabolites thereof which agreed with the oral fluid analysis was deemed to be a true negative (TN). A test not showing the presence of morphine and/or metabolites thereof which did not agree with the oral fluid analysis was deemed to be a false negative (FN).

- 5 The results of the tests done on the fingerprint samples taken from the people who had tested positive by oral fluid analysis are shown in Figure 13. The results above the horizontal cut off line are false negatives. The results below the horizontal cut off line are true positives.
- 10 The results of the tests done on the fingerprint samples taken from the people who had tested negative by oral fluid analysis are shown in Figure 14. The results above the horizontal cut off line are true negatives. The results below the horizontal cut off line are false positives.
- 15 The percentage accuracy, percentage sensitivity and percentage specificity of the lateral flow test for morphine and/or metabolites thereof can thus be calculated as follows:

Accuracy= $((\text{Total number of TP} + \text{Total number of TN}) / \text{Total number of samples}) \times 100$

Sensitivity = $(\text{Total number of TP} / (\text{Total number of TP} + \text{Total number of FN})) \times 100$

20 Specificity = $(\text{Total number of TN} / (\text{Total number of TN} + \text{Total number of FP})) \times 100$

The results showed that the accuracy of the lateral flow test, which can detect whether a sample has more or less than 180 pg of morphine, was 92.9 %. The sensitivity was 85.9 %. The specificity was 100 %.

25

Example 6:

Example 6 is identical to Example 5 with the exception that the drug metabolite tested was benzoylecgonine (BZE) (the major metabolite of cocaine), there were 100 people's samples taken (50 positive and 50 negative), and the cut-off point for the fingerprint samples was 150 pg of BZE, i.e. the fingerprint samples shown to comprise 150 pg or more of BZE were deemed positives whilst the fingerprint samples shown to comprise less than 150 pg of BZE were deemed negatives.

The results of the tests done on the fingerprint samples taken from the people who had tested positive by oral fluid analysis are shown in Figure 15. The results above the horizontal cut off line are false negatives. The results below the horizontal cut off line are true positives.

5

The results of the tests done on the fingerprint samples taken from the people who had tested negative by oral fluid analysis are shown in Figure 16. The results above the horizontal cut off line are true negatives. The results below the horizontal cut off line are false positives.

10

The results showed that the accuracy of the lateral flow test, which can detect whether a fingerprint sample has more or less than 150 pg BZE, was 95 %. The sensitivity was 90 %. The specificity was 100 %.

15

In the claims which follow and in the preceding description of the disclosure, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the disclosure.

20

Claims:

1. A method for analysing a sample comprising from 0.1 pg to 1 µg of an analyte, the method comprising:

5 providing a sample, the sample containing or not containing from 0.1 pg to 1 µg of the analyte of interest;

dissolving at least a portion of the sample in a buffer to form a dissolved sample solution;

10 contacting at least a portion of the dissolved sample solution with a probe zone comprising a labelled probe to dissolve at least a portion of the labelled probe and allow the labelled probe to bind with the analyte, where present, in the portion of the dissolved sample solution to form a labelled probe-analyte complex;

15 passing the labelled probe and/or labelled probe-analyte complex through a test site comprising a first immobilised capture reagent capable of binding to the labelled probe;

determining whether or not the amount of analyte, if any, in the sample exceeds a threshold value by detecting the amount of labelled probe in the test site; wherein the sample comprises finger-sweat and/or palm-sweat and/or toe-sweat; wherein the sample is provided on a sample receiving portion of a lateral flow device, the 20 device further comprising:

the probe zone downstream of the sample receiving portion;

the test site downstream of the probe zone, comprising a first immobilised capture reagent capable of binding to the labelled probe;

25 the device being configured to permit movement of a buffer from the sample receiving portion to the probe zone and from the probe zone to the test site;

wherein the sample provided is substantially dry, such that the sample comprises insufficient liquid to move from the sample receiving portion to the probe zone wherein the sample is provided directly to the sample receiving portion;

30 wherein dissolving at least a portion of the sample in a buffer to form a dissolved sample solution is carried out by providing the buffer upstream of the sample receiving portion and passing the buffer through the sample receiving portion.

advantageously

2. The method of claim 1, wherein the sample comprises finger-sweat.

3. The method of any of claims 1 or 2, wherein the sample is provided in step (a) as a fingerprint, the fingerprint comprising sweat deposited as an impression of a finger's ridge pattern.

5

4. The method of any of claims 1 to 3, wherein the buffer is provided in a volume of from 100 to 500 μ l.

10 5. The method of any of claims 1 to 4, wherein the buffer to sample volume ratio is from 50:1 to 1,000 to 1.

6. The method of any of claims 1 to 5, wherein the buffer comprises:

15 a water miscible organic solvent;
a surfactant; and
a buffering agent.

7. The method of claim 6, wherein the surfactant may be a detergent.

20 8. The method of claims 6 or 7, wherein:
the water miscible organic solvent comprises one or more of ethanol, methanol and tetrahydrofuran; and/or
the surfactant comprises one or more of Tween-20, Tween 80, Triton X-100 and
25 tetraoctyl ammonium bromide; and/or
the buffering agent comprises one or more of HEPES, Tris, TRIZMA and phosphate buffer.

30 9. The method of claims 6 to 8, wherein the buffer comprises 10 to 30 v/v % water miscible solvent, 0.1 to 0.30 w/v % surfactant and 5 to 10 mM buffering agent.

10. The method of any of claims 1 to 9, wherein the sample comprises from 0.1 pg to 5 ng of analyte.

35

11. The method of any of claims 1 to 10, wherein the probe is selected from the group consisting of an antibody, an aptamer, an affimer, and mixtures thereof, 5 advantageously wherein the probe is an antibody.
12. The method of any of claims 1 to 11, wherein the probe zone comprises two or more different antibodies.
- 10 13. The method of any of claims 1 to 12, wherein the probe comprises divalent antibodies and/or monovalent antibody Fab fragments.
14. The method of any of claims 1 to 13, wherein the first immobilised capture reagent comprises an antigen capable of binding to the labelled probe.
- 15 15. The method of any of claims 1 to 14, wherein the first immobilised capture reagent comprises two or more different antigens capable of binding to the labelled probe.
- 20 16. The method of any of claims 1 to 15, wherein the analyte, if present, comprises a drug metabolite and/or a drug.
17. The method of any of claims 1 to 16, further comprising:
 - (f) passing the labelled probe and/or the labelled probe-analyte complex through a control site comprising a second immobilised capture reagent capable of binding to the labelled probe and to the labelled probe-analyte complex; and
 - 25 (g) determining whether or not the test result is reliable by detecting or not detecting the labelled probe and/or the labelled probe-analyte complex in the control site.
- 30 18. The method of any of claims 1 to 17, wherein the labelled probe is detectable in radiation having a wavelength of 400 nm to 1 mm, and wherein step (e) and/or step (g) is carried out by illuminating the test site and/or the first control site with radiation having a wavelength of 400 nm to 1 mm to show the labelled probe and/or labelled probe-analyte complex, if present.

19. The method of any of claims 1 to 18, further comprising:

(h) illuminating a normalisation site with radiation having a wavelength of 400 nm to 1 mm, measuring the signal intensity of the normalisation site and comparing said signal intensity to the signal intensity detected at the test site and/or the control site;

5 wherein the normalisation site comprises an immobilised labelled protein incapable of binding to the labelled probe, the analyte, and any labelled probe-analyte complex comprising the labelled probe and the analyte; and

wherein the immobilised labelled protein and the labelled probe are labelled with the same label.

10 20. The method of any of claims 1 to 19, further comprising obtaining a fingerprint pattern on a fingerprint pattern receiving zone, wherein the fingerprint pattern receiving zone is separate to the sample receiving portion but is housed within the same device.

15 21. The method of claim 20, further comprising scanning and/or recording the fingerprint pattern.




Figure 1





Figure 2

Fingerprint Collection Pad Material: Ahlstrom Grade 121



Donor: 04745007
Negative for MOR


Donor: 04745009
>10 ng/ml MOR

Donor: 04745008
>1700 ng/ml MOR

Figure 3

5s exposure time

Fingerprint Collection Pad Material: Ahlstrom Grade 142



Donor: 04745007
Negative for MOR


Donor: 04745009
>10 ng/ml MOR

Donor: 04745008
>1700 ng/ml MOR

5s exposure time

Figure 4

Fingerprint Collection Pad Material: Ahlstrom Grade 8951



Donor: 04745007
Negative for MOR
Donor: 04745009
>10 ng/ml MOR
Donor: 04745008
>1700ng/ml MOR

5s exposure time

Figure 5


Fingerprint Collection Pad Material: Ahlstrom Grade 1281



5s exposure time

Figure 6


*40ug/ml BSA-Morphine stock (test line)
0.25 μ l/cm deposition)
50ng labelled antibody in conjugate pad*



For detection around the opiate Cut-off

Figure 7


*40ug/ml BSA-Morphine stock (test line)
0.25 μ l/cm deposition)
100ng labelled antibody in conjugate pad*



Decreased sensitivity for higher gross detection

Figure 8


*80ug/ml BSA-Morphine stock (test line
0.25 μ l/cm deposition)
50ng antibody in conjugate pad*



0pg 150pg 300pg 450pg

Figure 9

*80ug/ml BSA-Morphine stock (test line
0.25 μ l/cm deposition)
100ng antibody in conjugate pad*



0pg 150pg 300pg 450pg

Figure 10




Figure 11




Figure 12





Figure 13

BSA-MOR Lateral Flow Assay - MOR Metabolite Standards and Negative Control Fingerprints



Sample Identifiers

Figure 14




Figure 15




Figure 16